Xenetic Biosciences: Renaissance Reports 137,440 Shares

Xenetic Biosciences, Inc. amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 137,440 shares of Common Stock, equal to 6.00% of the class.

Rhea-AI Filing Summary

Xenetic Biosciences, Inc. amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 137,440 shares of Common Stock, equal to 6.00% of the class. The filing notes certain funds managed by RTC have rights to dividends and sale proceeds.

Insights

Institutional Ownership Analyst

Large quantitative manager reports a 6.00% holding in XBIO.

Renaissance Technologies LLC and affiliated RTHC are recorded as holding 6.00% ( 137,440 shares) of Common Stock. The statement is an amendment to a prior Schedule 13G filing and updates ownership disclosure.

The filing also states that certain funds managed by RTC have rights to dividends and sale proceeds; cash‑flow treatment is therefore linked to those managed funds. Subsequent filings would show any changes to this position.

Key Figures

Beneficial ownership: 137,440 shares Percent of class: 6.00% CUSIP: 984015602 +3 more

6 metrics

Beneficial ownership 137,440 shares Amount beneficially owned (Item 4)

Percent of class 6.00% Percent of class (Item 4)

CUSIP 984015602 CUSIP for Common Stock on cover

Filing type SCHEDULE 13G/A Amendment No. 1 to prior Schedule 13G

Reporting entities Renaissance Technologies LLC; Renaissance Technologies Holdings Corporation Names of persons filing (Item 2)

Signature date 05/14/2026 Signed date on the filing

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) Xenetic Biosciences, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 137440"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power financial

"(iii) Sole power to dispose or to direct the disposition of: 137440"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Renaissance report in Xenetic Biosciences (XBIO)?

Renaissance reports beneficial ownership of 137,440 shares, representing 6.00% of the class. The Schedule 13G/A lists sole voting and dispositive power over those shares for the reporting entities.

Who filed the Schedule 13G/A for XBIO?

The filing was made by Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation. Addresses and citizenship are shown as Delaware entities with a New York principal office.

Does the filing say Renaissance controls dividends or sale proceeds for XBIO shares?

The filing states certain funds managed by RTC have the right to receive dividends and proceeds from sales of the reported securities. This identifies managed funds as beneficial recipients.

Is this a new acquisition or an amendment to prior disclosure for XBIO?

This is labeled Amendment No. 1 to a Schedule 13G, indicating it updates a prior beneficial ownership statement rather than announcing a new corporate transaction.

What CUSIP and class are covered in the XBIO filing?

The filing covers Common Stock, $0.001 par value of Xenetic Biosciences with CUSIP 984015602, as stated on the cover information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:47 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Xenetic Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

984015602

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 984015602

1

Names of Reporting Persons

Renaissance Technologies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 137,440.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 137,440.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

137,440.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.00 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 984015602

1

Names of Reporting Persons

Renaissance Technologies Holdings Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 137,440.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 137,440.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

137,440.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.00 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Xenetic Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 945 CONCORD ST., FRAMINGHAM, MA 01701
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b)	Address or principal business office or, if none, residence: 800 Third Avenue New York, New York 10022
(c)	Citizenship: RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 984015602
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 137440
(b)	Percent of class: 6.00 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 137440
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 137440
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Renaissance Technologies LLC

Signature:	Brian Felczak
Name/Title:	Chief Financial Officer
Date:	05/14/2026

Renaissance Technologies Holdings Corporation

Signature:	Brian Felczak
Name/Title:	Vice President
Date:	05/14/2026

Exhibit Information

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, $0.001 par value per share of Xenetic Biosciences, Inc.